Targets › TNFRSF1B
1 program from 1 company in 1 trial: 1 Phase 1; Hematology.
Receptor for TNF/TNFSF2 and LTA/TNFSF1, which activates the tumor necrosis factor-mediated (TNF) signaling pathway upon ligand-binding. Has high affinity for TNFSF2/TNF and approximately 5-fold lower affinity for LTA/TNFSF1. (UniProt, P20333)
Open in Phaseline: the race on TNFRSF1B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sichuan Clover Biopharmaceuticals | SCB-219M TNF receptor II-Fc fusion protein with TPO mimetic peptide | TNFRSF1B, THPO | Phase 1 | Chemotherapy-induced Thrombocytopenia (CIT) | – |
Chemotherapy-induced Thrombocytopenia (CIT) (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.